Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

[pSer9]GSK-3β monoclonal antibody (3A8)

ADI-905-761-100 100 µg 433.00 USD
Do you need bulk/larger quantities?

Product Details

Alternative Name:Glycogen synthase kinase-3β
Immunogen:Synthetic peptide corresponding to a portion of GSK-3β phosphorylated at Ser9.
UniProt ID:P49841
Species reactivity:Human, Mouse, Rat
Applications:ELISA, WB
Purity Detail:Thiophilic adsorption and size exclusion chromatography purified.
Formulation:Lyophilized from 1ml of 2x PBS containing 0.09% sodium azide, PEG, and sucrose.
Reconstitution:Reconstitute with 1ml water (15 minutes at room temperature).
Use/Stability:Stable at -80°C up to 1 year, at 4°C up to 3 months.
Handling:Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -80°C.
Shipping:Shipped on Blue Ice
Long Term Storage:-20°C
Scientific Background:Glycogen Synthase Kinase 3β (GSK-3β) is a unique serine/threonine kinase that is inactivated by phosphorylation. In response to insulin binding, PKB/AKT phosphorylates GSK-3β on serine 9, which prevents GSK-3β from phosphorylating glycogen synthase. Unphosphorylated glycogen synthase is active and able to synthesize glycogen. GSK-3β is also unique in that it requires a substrate that has been phosphorylated by a distinct kinase before it can phosphorylate the substrate. This phosphate priming mechanism explains why phosphorylation of serine 9 inactivates GSK-3β. The phosphorylated serine binds to the GSK-3β priming phosphate position and prevents binding of alternative substrates. In addition to insulin signaling, GSK-3β participates in the Wnt signaling pathway, where it forms a complex with axin, beta-catenin and adenomatous polyposis coli (APC) protein. In the presence of Wnts, GSK-3β is unable to phosphorylate beta-catenin, which leads to stabilization of beta-catenin. The Wnt pathway inactivates GSK-3β via the proteins, Dishevelled and FRAT, which disrupt the interaction of GSK-3β with axin, beta-catenin, and APC. Clinically, there is considerable interest in GSK-3β inhibitors because they may mimic the effect of insulin or reduce the hyperphosphorylation of Tau that is observed in Alzheimer's Disease.
Regulatory Status:RUO - Research Use Only
[pSer9]GSK-3β monoclonal antibody (3A8) Western blot
Western blot analysis of AY31 cells untreated (co), EGF stimulated (EGF), or pervanadate treated (VH), with GSK3β (phospho-Ser9) mAb (3A8).
Please mouse over
[pSer9]GSK-3β monoclonal antibody (3A8) Western blot

Product Literature References

α-Synuclein Binds to the ER-mitochondria Tethering Protein VAPB to Disrupt Ca2+ Homeostasis and Mitochondrial ATP Production: S. Paillusson, et al.; Acta Neuropathol. 134, 129 (2017), Abstract; Full Text

Related Literature

Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

Stem Cells
Stem Cells
Download as PDF

Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

Keep in touch

©2021 Enzo Life Sciences, Inc.,